超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

英國Enigma Diagnostics  
Enigma DiagnosticsLimited是一家總部位于英國的未上市公司，致力于為分散和即時設置開發新一代快速分子診斷儀器平臺。

　　Enigma的創新型專有技術將實時聚合酶鏈反應的速度和靈敏度與現場分散與即時測試所需的簡易性相結合，可以在45分鐘之內提供原始樣本的測試結果。

　　該公司正瞄準眾多價值數十億英磅的市場，重點則放在臨床和高值應用市場。Enigma的商業戰略是最大化其市場領先的快速診斷即時與現場設備與化驗平臺的持續運轉帶來的營收，這些設備和平臺來源于該公司廣泛的已發布和提交專利申請的知識產權組合。Enigma將與一些市場領導者合作，這些市場領導者需要有全球的市場滲透力，并且要適當建立內部銷售和營銷能力以指導其產品的分銷過程。

　　Enigma 擁有 Defence Science TechnologyLaboratory授予的一系列專利（這些專利體現了英國國防部 (UK Ministry ofDefence)逾15年來對研究的大力支持）的獨家許可以及美國應用生物系統公司 (Applied Biosystems) 和CeleraLicences的實時聚合酶鏈反應設備推廣的許可。Enigma的研發活動已經產生了50多個致力于實時聚合酶鏈反應和更廣泛分子技術的全球專利系列。這些專利中有許多已經得到美國、歐盟和日本等核心商業地區的承認，并且在眾多其它關鍵地區也有范圍更廣的申請和授權。

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.